Zacks Investment Research
07 Sept 2026, 16:26 UTC · 3d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Novartis' phase III Lp(a)HORIZON study for pelacarsen failed to meet its primary endpoint of reducing major adverse cardiovascular events. — A failed Phase III trial for a major drug candidate is a significant negative catalyst for the developing company and its partners.
-0.60The failure of Novartis' trial increases the risk profile for Amgen's similar Lp(a)-lowering drug, olpasiran, currently in Phase III trials. — Clinical failure in a specific drug class suggests a potential lack of efficacy for the biological mechanism, threatening the valuation of competing pipeline assets.
-0.50Amgen shares fell 5% in after-hours trading following the Novartis announcement. — Immediate market devaluation reflects investor concerns over the viability of Amgen's cardiovascular siRNA program.
-0.30Continue reading
5 related stories
Top 1 mover · tap to explore
Shares of Novartis and Ionis Pharmaceuticals declined following the announcement of the study results. — Direct negative impact on the companies responsible for the failed drug's development and commercialization rights.
-0.30Which stocks this story touches
The company's phase III Lp(a)HORIZON study failed to meet its primary endpoint, leading to a decline in share price.
Shares declined following the failed study results of pelacarsen, a drug licensed to Novartis.
Shares fell and the risk profile of its Lp(a) program increased following a failed phase III study by a competitor in the same field.
[mutual] Novartis secured global rights from Ionis Pharmaceuticals to develop, manufacture, and commercialize pelacarsen under a licensing and collaboration agreement.
[mutual] Both companies are developing investigational therapies to reduce Lp(a) synthesis in patients with cardiovascular disease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13h ago
